Vaccines Market

7500+ companies worldwide approach us every year for their revenue growth initiatives

Global top 2000 strategist rely on us for their growth strategies.

80% of fortune 2000 companies rely on our research to identify new revenue sources.

30000 High Growth Opportunities

95% renewal rate

KNOW MORE

Vaccines Market by Technology (Recombinant, Toxoid, Conjugate, RNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Influenza, DTP, HPV, MMR, COVID-19), Route of Administration (IM, SC, Oral), End User (Pediatric, Adult) & Region - Global Forecast to 2026

FREE BROCHURE FREE SAMPLE REPORT

Report Code: PH 6528 Jan, 2022, by marketsandmarkets.com

Inquire Before Buying

Updated on : May 29, 2023

The global vaccines market in terms of revenue was estimated to be worth $41.4 billion in 2021 and is poised to reach $67.2 billion by 2026, growing at a CAGR of 10.2% from 2021 to 2026. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growing government support and focus for development of vaccine & immunization, and increasing prevalence of infectious diseases, are driving the market. However, for the development of vaccines the low purchasing power and huge capital may restrain the market growth in the developing countries.

To know about the assumptions considered for the study, Request for Free Sample Report

Vaccines Market

Vaccines Market Dynamics

Driver: Growing prevalence of emerging and re-emerging infectious diseases

With people coming into closer contact with wild animals, traveling much more frequently and far greater distances than in the past and living in more densely populated areas, the potential for emerging infectious diseases to spread rapidly and cause global epidemics is a major concern. Additionally, also there is the potential for diseases to emerge as a result of deliberate introduction into animal, human, or plant populations for terrorist purposes. Their are about 40 infectious diseases that have been discovered, including SARS, MERS, Ebola, chikungunya, avian flu, swine flu, Zika, and most recently COVID-19. Experts have warned of future pandemics and epidemics to be even more lethal than COVID-19. The rising prevalence of these infectious diseases will ensure a continued and growing demand for vaccines in the coming years. Thus, factors like the emergence of new diseases will ensure better R&D funding initiatives, strong pipeline, and new vaccine opportunities for large population segments and drive the market growth.

Restraint: High cost of vaccine development

Development of Vaccines is a huge capital intensive procedure. The storage and distribution cost of vaccines is higher than any other pharmaceutical product, as it requires monitoring devices and specialized equipment. The lack of proper storage and distribution facilities can deteriorate vaccine efficiency and quality. The development process (from in vitro research to marketing) takes 10–15 years and requires an investment of USD 800 million–1 billion. Moreover, as the success rate of vaccine development is low, manufacturers find it challenging to manage operational costs and obtain initial investments. Thus, the high cost of vaccine development and storage is restraining market growth.

Opportunity: High growth prospects in emerging markets

Emerging markets, such as China, India, and Southeast Asia, showcase growing opportunities for the vaccine industry due to their growing patient populations and increasing disposable incomes. This growth potential has drawn major market players to invest in these economies. Additionally, Companies are investing in and focusing on developing low-cost, affordable, vaccines to strengthen the reach of immunization programs in these economies.

Challenge: Inequitable access to vaccines

This is a key issue in the market, particularly in poverty-stricken regions where awareness programs and initiatives have either not penetrated sufficiently. In other cases, vaccines may not be easily accessible, such as in remote regions, due to a lack of sufficient storage facilities and government support. Other factors, such as low literacy rates and a lack of health education and financial resources, have also restrained access to immunization

Conjugate vaccines segment of Vaccines Market is accounted for the largest share of the technology segment (excluding COVID 19 vaccines)

On the basis of technology, the market (excluding COVID 19 vaccines) has been categorized into recombinant vaccines, conjugate vaccines, inactivated & subunit vaccines, live attenuated vaccines, toxoid vaccines, and other vaccines such as mRNA vaccines, DNA vaccines, and viral vector vaccines. By technology, the conjugate vaccines segment dominated the global market (excluding COVID-19 vaccines). Factors such as growing government support and investments in development of conjugate vaccine drives the market.

The Pneumococcal disease segment of Vaccines Market is accounted for the largest share

On the basis of disease indication, the market is segmented into influenza, pneumococcal disease, combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, COVID-19, and other disease indications. The pneumococcal disease segment dominated the market with largest share, by disease indication. Factors such as, investments by government in pneumococcal vaccination programs and high incidence of pneumococcal disease drives the market.

Monovalent vaccines segment accounted for the largest share of the type segment of Vaccines Market

On the basis of type, the global market is divided into monovalent and multivalent vaccines. The monovalent vaccines segment accounted for the largest share of the global market (excluding COVID-19 vaccines). Factors such as growing prevalence of emerging diseases has prompted initiatives for immunization against specific infectious diseases such as COVID 19 and R&D initiatives will contrive to drive the market for monovalent vaccines.

Pediatric vaccines segment accounted for the largest share of the end user segment of Vaccines Market

On the basis of end user, the market is segmented into pediatric and adult users. The pediatric users segment accounted for the largest share of the market (excluding COVID 19 vaccines), while the adult user segment is estimated to register the highest CAGR during the forecast period. Factors such as, growing government initiatives and growing company initiatives to develop advanced pediatric vaccines for preventing diseases are expected to drive market growth for pediatric vaccines.

Intramuscular & Subcutaneous route of administration segment accounted for the largest share of the route of administration segment of Vaccines Market

On the basis of route of administration, the market is divided into intramuscular and subcutaneous administration, oral administration, and other routes of administration. The intramuscular and subcutaneous administration segment accounted for the largest share of the market (excluding COVID-19 vaccines). Benefits such as, administration rate, precise control of dose, and ease of administration makes the Intramuscular & Subcutaneous as one of the most prevalent route and thus drives the market.

Vaccines Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America accounted for the largest regional market for Vaccine market.

On the basis of region, the market is broadly categorized into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America accounted for the largest share of the market. Factors such as mandatory reporting, and increasing prevalence rate of infectious diseases, drives the market in North America.

Key players operating in the vaccine market include GlaxoSmithKline Plc (UK), Merck & Co., Inc. (US), Sanofi SA (France), and Pfizer, Inc. (US).

Vaccines Market Report Scope

Report Metric	Details
Market Revenue in 2021	$41.4 billion
Projected Revenue by 2026	$67.2 billion
Revenue Rate	Poised to grow at a CAGR of 10.2%
Market Driver	Growing prevalence of emerging and re-emerging infectious diseases
Market Opportunity	High growth prospects in emerging markets

This report categorizes the vaccine market to forecast revenue and analyze trends in each of the following submarkets:

By Technology (excluding COVID 19 vaccines)

Conjugate vaccines
Inactivated & Subunit vaccines
Live Attenuated vaccines
Recombinant vaccines
Toxoid vaccines
Viral vector vaccines

COVID 19 Vaccine Market, By Technology

mRNA vaccines
Viral Vector vaccines
Other vaccines (inactivated, recombinant, conjugate, subunit, peptide, and DNA vaccines)

By Type

Monovalent vaccines
Multivalent vaccines

By Disease Indication

Influenza
Pneumococcal diseases
Combination vaccines
HPV
Herpes Zoster
Meningococcal diseases
Rotavirus
MMR
Varicella
Hepatitis
DTP
Polio
COVID 19
Other disease indications (cancer, dengue, tuberculosis, typhoid, Japanese encephalitis, rabies, yellow fever, and allergies)

By Route of Administration

Intramuscular & Subcutaneous administration
Oral administration
Other routes of administration (intranasal, intradermal, and percutaneous)

By End-User (excluding COVID 19 vaccines)

Pediatric vaccines
Adult vaccines

By Region

North America
- US
- Canada
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe (RoE)
Asia Pacific (APAC)
- Japan
- China
- India
- South Korea
- Rest of Asia Pacific (RoAPAC)
Latin America
- Brazil
- Rest of Latin America (RoLA)
- Middle East & Africa

Recent Developments

In October 2021, Pfizer received the US FDA Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age.
In August 2021, Pfizer-BioNTech COVID-19 vaccine COMIRNATY received full US FDA approval for individuals 16 years and older.
In July 2021, GSK received US FDA approval for Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 18 years and older who are or will be at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy.
In June 2021, Merck announced the launch of VAXELIS (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine) in the US, developed in partnership with Sanofi Pasteur.

Frequently Asked Questions (FAQ):

What is the projected market revenue value of the global vaccines market?

The global vaccines market boasts a total revenue value of $67.2 billion by 2026.

What is the estimated growth rate (CAGR) of the global vaccines market?

The global vaccines market has an estimated compound annual growth rate (CAGR) of 10.2% and a revenue size in the region of $41.4 billion in 2021.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 38)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
                    TABLE 1 VACCINES MARKET: INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
                    FIGURE 1 VACCINE MARKET SEGMENTATION
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 44)
    2.1 RESEARCH DATA
           FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 3 BREAKDOWN OF PRIMARIES: VACCINES MARKET
    2.2 MARKET ESTIMATION METHODOLOGY
           FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2020
           2.2.1 INSIGHTS FROM PRIMARY EXPERTS
                    FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
    2.3 MARKET GROWTH RATE PROJECTIONS
           FIGURE 6 CAGR PROJECTIONS (SUPPLY-SIDE): VACCINES MARKET (EXCLUDING COVID-19 VACCINES)
           FIGURE 7 VACCINES MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS
    2.4 DATA TRIANGULATION
           FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.5 RESEARCH ASSUMPTIONS
    2.6 RISK ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 54)
    FIGURE 9 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
    FIGURE 10 COVID-19 VACCINE MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
    FIGURE 11 MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021 VS. 2026 (USD MILLION)
    FIGURE 12 MARKET, BY DISEASE INDICATION, 2021 VS. 2026 (USD MILLION)
    FIGURE 13 MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021 VS. 2026 (USD MILLION)
    FIGURE 14 MARKET SHARE (EXCLUDING COVID-19 VACCINES), BY END USER, 2021 VS. 2026
    FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET (EXCLUDING COVID-19 VACCINES)

4 PREMIUM INSIGHTS (Page No. - 60)
    4.1 VACCINES MARKET OVERVIEW (EXCLUDING COVID-19 VACCINES)
           FIGURE 16 GROWING PREVALENCE OF EMERGING AND RE-EMERGING INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY AND COUNTRY (2020)
           FIGURE 17 CONJUGATE VACCINES ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2020
    4.3 VACCINES MARKET (EXCLUDING COVID-19 VACCINES): GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 18 ASIA PACIFIC TO WITNESS THE HIGHEST GROWTH IN THE VACCINES MARKET FROM 2021 TO 2026

5 MARKET OVERVIEW (Page No. - 63)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 19 VACCINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Growing prevalence of emerging and re-emerging infectious diseases
                               TABLE 2 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
                    5.2.1.2 Increasing focus on immunization programs
                    5.2.1.3 Growing government support for vaccine development
                               TABLE 3 NIH FUNDING FOR VACCINE RESEARCH, 2018–2022 (USD MILLION)
                    5.2.1.4 Increasing industry initiatives to enhance vaccine R&D
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of vaccine development
                    5.2.2.2 Low purchasing power in developing countries
           5.2.3 OPPORTUNITIES
                    5.2.3.1 High growth prospects in emerging markets
                    5.2.3.2 Focus on therapeutic vaccines
                    5.2.3.3 Use of adjuvants in vaccines
           5.2.4 CHALLENGES
                    5.2.4.1 Inequitable access to vaccines
                               TABLE 4 IMMUNIZATION COVERAGE, BY DISEASE, 2020
    5.2.4.2 Vaccine misinformation
    5.3 IMPACT OF COVID-19 ON THE VACCINE MARKET
           TABLE 5 APPROVED COVID-19 VACCINES (NOVEMBER 2021)
           TABLE 6 COVID-19 VACCINES PIPELINE
           FIGURE 20 VACCINES MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019–2021 (USD BILLION)
    5.4 RANGES/SCENARIO
           FIGURE 21 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE VACCINES MARKET
    5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS
           FIGURE 22 REVENUE SHIFT & NEW REVENUE POCKETS FOR VACCINE PROVIDERS
    5.6 PATENT ANALYSIS
           FIGURE 23 PATENTS GRANTED FOR VACCINES IN THE LAST 10 YEARS
           TABLE 7 INDICATIVE LIST OF PATENTS IN THE VACCINE MARKET
    5.7 PRICING ANALYSIS
           TABLE 8 MEDIAN PRICE PER DOSE OF SOME VACCINES (2020) (USD)
    5.8 VALUE CHAIN ANALYSIS
           FIGURE 24 VALUE CHAIN ANALYSIS OF THE VACCINES MARKET: R&D AND CLINICAL TRIAL PHASE CONTRIBUTES MAXIMUM VALUE
    5.9 ECOSYSTEM ANALYSIS
           FIGURE 25 ECOSYSTEM ANALYSIS: VACCINES MARKET
    5.10 REGULATORY LANDSCAPE
           FIGURE 26 REGULATORY APPROVAL PROCESS FOR VACCINES
           5.10.1 NORTH AMERICA
           5.10.2 EUROPE
                    TABLE 9 REGULATORY AUTHORITIES IN EUROPE
           5.10.3 ASIA PACIFIC
                    TABLE 10 REGULATORY AUTHORITIES IN ASIA PACIFIC
           5.10.4 REST OF THE WORLD
    5.11 PORTER’S FIVE FORCES ANALYSIS

                       TABLE 11 VACCINE MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.11.1 THREAT OF NEW ENTRANTS
           5.11.2 THREAT OF SUBSTITUTES
           5.11.3 BARGAINING POWER OF BUYERS
           5.11.4 BARGAINING POWER OF SUPPLIERS
           5.11.5 INTENSITY OF COMPETITIVE RIVALRY
    5.12 KEY PIPELINE PRODUCTS

          TABLE 12 KEY PIPELINE VACCINES: GLAXOSMITHKLINE PLC (UK)
                    TABLE 13 KEY PIPELINE VACCINES: PFIZER, INC. (US)
                    TABLE 14 KEY PIPELINE VACCINES: MERCK & CO., INC. (US)
                   TABLE 15 KEY PIPELINE VACCINES: SANOFI S.A. (FRANCE)
    5.13 NEW VACCINE OPPORTUNITIES
           5.13.1 HIV
                    5.13.1.1 HIV vaccines pipeline
                    5.13.1.2 HIV vaccines: Public-private initiatives and funding
           5.13.2 MALARIA
                    5.13.2.1 Malaria vaccines pipeline
                    5.13.2.2 Malaria vaccines: Public-private initiatives and funding
           5.13.3 ZIKA
                    5.13.3.1 Zika vaccines pipeline
                    5.13.3.2 Zika vaccines: Public-private initiatives and funding
           5.13.4 EBOLA
                    5.13.4.1 Ebola vaccines pipeline
                    5.13.4.2 Ebola vaccines: Public-private initiatives and funding
                    5.13.4.3 Ebola projects funded by EC (2014–2020)

6 VACCINES MARKET, BY TECHNOLOGY (Page No. - 93)
    6.1 INTRODUCTION
           TABLE 16 MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 17 COVID-19 VACCINE MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
    6.2 CONJUGATE VACCINES
           6.2.1 CONJUGATE VACCINES HOLD THE LARGEST SHARE OF THE MARKET
                    TABLE 18 COST OF PEDIATRIC MENINGOCOCCAL CONJUGATE VACCINES AVAILABLE IN THE US
                    TABLE 19 COST OF ADULT MENINGOCOCCAL CONJUGATE VACCINES AVAILABLE IN THE US
                    TABLE 20 CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                    TABLE 21 NORTH AMERICA: CONJUGATE MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 22 EUROPE: CONJUGATE MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 23 ASIA PACIFIC: CONJUGATE MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 24 LATIN AMERICA: CONJUGATE MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
    6.3 RECOMBINANT VACCINES
           6.3.1 LACK OF POST-VACCINATION REACTIONS AND REDUCED NEED FOR BOOSTER DOSES ARE DRIVING R&D ON RECOMBINANT VACCINES
                    TABLE 25 EXAMPLES OF RECOMBINANT VACCINES
                    TABLE 26 RECOMBINANT VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                    TABLE 27 NORTH AMERICA: RECOMBINANT MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 28 EUROPE: RECOMBINANT MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 29 ASIA PACIFIC: RECOMBINANT MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 30 LATIN AMERICA: RECOMBINANT MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
    6.4 INACTIVATED & SUBUNIT VACCINES
           6.4.1 EASE OF STORAGE AND TRANSPORTATION HAVE MADE INACTIVATED & SUBUNIT VACCINES POPULAR
                    TABLE 31 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES
                    TABLE 32 INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                    TABLE 33 NORTH AMERICA: INACTIVATED & SUBUNIT MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 34 EUROPE: INACTIVATED & SUBUNIT MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 35 ASIA PACIFIC: INACTIVATED & SUBUNIT MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 36 LATIN AMERICA: INACTIVATED & SUBUNIT MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
    6.5 LIVE ATTENUATED VACCINES
           6.5.1 ISSUES IN PRESERVING AND MAINTAINING LIVE ATTENUATED VACCINES HAVE SLOWED MARKET GROWTH
                    TABLE 37 EXAMPLES OF LIVE ATTENUATED VACCINES
                    TABLE 38 LIVE ATTENUATED VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                    TABLE 39 NORTH AMERICA: LIVE ATTENUATED MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 40 EUROPE: LIVE ATTENUATED MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 41 ASIA PACIFIC: LIVE ATTENUATED MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 42 LATIN AMERICA: LIVE ATTENUATED MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
    6.6 TOXOID VACCINES
           6.6.1 COMPANY INITIATIVES AND THE INTRODUCTION OF NEW VACCINES WILL SUPPORT MARKET GROWTH
                    TABLE 43 EXAMPLES OF TOXOID VACCINES
                    TABLE 44 TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                    TABLE 45 NORTH AMERICA: TOXOID MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 46 EUROPE: TOXOID MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 47 ASIA PACIFIC: TOXOID MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 48 LATIN AMERICA: TOXOID MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
    6.7 VIRAL VECTOR VACCINES
           6.7.1 VIRAL VECTOR VACCINES USE THE BODY’S OWN CELLS TO PRODUCE ANTIGENS
                    TABLE 49 EXAMPLES OF RECENTLY LAUNCHED VIRAL VECTOR VACCINES
                    TABLE 50 VIRAL VECTOR VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)

7 VACCINES MARKET, BY TYPE (Page No. - 112)
    7.1 INTRODUCTION
           TABLE 51 VACCINE MARKET (INCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
           TABLE 52 MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
    7.2 MONOVALENT VACCINES
           7.2.1 MONOVALENT VACCINES DOMINATE THE VACCINE MARKET
                    TABLE 53 EXAMPLES OF MONOVALENT VACCINES
                    TABLE 54 MONOVALENT MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                    TABLE 55 NORTH AMERICA: MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 56 EUROPE: MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 57 ASIA PACIFIC: MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 58 LATIN AMERICA: MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
    7.3 MULTIVALENT VACCINES
           7.3.1 INCREASING INITIATIVES BY COMPANIES TO DEVELOP NEW MULTIVALENT VACCINES TO DRIVE MARKET GROWTH
                    TABLE 59 EXAMPLES OF MULTIVALENT VACCINES
                    TABLE 60 MULTIVALENT VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                    TABLE 61 NORTH AMERICA: MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 62 EUROPE: MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 63 ASIA PACIFIC: MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 64 LATIN AMERICA: MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)

8 VACCINES MARKET, BY DISEASE INDICATION (Page No. - 120)
    8.1 INTRODUCTION
           TABLE 65 VACCINE MARKET, BY DISEASE INDICATION, 2019–2026 (USD MILLION)
    8.2 PNEUMOCOCCAL DISEASE
           8.2.1 PNEUMOCOCCAL DISEASE IS THE LARGEST DISEASE INDICATION SEGMENT OF THE MARKET
                    TABLE 66 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL VACCINES IN THE MARKET
                    TABLE 67 PNEUMOCOCCAL DISEASE VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 68 NORTH AMERICA: PNEUMOCOCCAL DISEASE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 69 PNEUMOCOCCAL DISEASE MARKET, BY BUYER, 2019–2026 (MILLION DOSES)
    8.3 INFLUENZA
           8.3.1 RISING DEMAND FOR INFLUENZA VACCINES FOR IMMUNIZATION AGAINST VIRAL INFECTIONS TO DRIVE MARKET GROWTH
                    TABLE 70 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES IN THE MARKET
                    TABLE 71 INFLUENZA VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 72 NORTH AMERICA: INFLUENZA VACCINE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.4 COMBINATION VACCINES
           8.4.1 INCREASING DEMAND FOR ALL-IN-ONE VACCINES IS DRIVING THE GROWTH OF THIS SEGMENT
                    TABLE 73 LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES IN THE MARKET
                    TABLE 74 COMBINATION VACCINE MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 75 NORTH AMERICA: COMBINATION MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.5 HPV
           8.5.1 HPV VACCINES MARKET TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
                    TABLE 76 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET
                    TABLE 77 HPV MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 78 NORTH AMERICA: HPV MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 79 HPV MARKET, BY BUYER, 2019–2026 (MILLION DOSES)
    8.6 MENINGOCOCCAL DISEASE
           8.6.1 RISING INCIDENCE OF MENINGOCOCCAL DISEASE TO SUPPORT THE GROWTH OF THIS SEGMENT
                    TABLE 80 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES IN THE MARKET
                    TABLE 81 MENINGOCOCCAL DISEASE VACCINE MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 82 NORTH AMERICA: MENINGOCOCCAL DISEASE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.7 HERPES ZOSTER
           8.7.1 HERPES ZOSTER VACCINES TO WITNESS STABLE DEMAND DURING THE FORECAST PERIOD
                    TABLE 83 HERPES ZOSTER MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 84 NORTH AMERICA: HERPES ZOSTER MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.8 ROTAVIRUS
           8.8.1 RISING INCIDENCE OF ROTAVIRUS INFECTIONS TO DRIVE MARKET GROWTH
                    TABLE 85 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES IN THE MARKET
                    TABLE 86 ROTAVIRUS VACCINE MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 87 NORTH AMERICA: ROTAVIRUS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 88 ROTAVIRUS MARKET, BY BUYER, 2019–2026 (MILLION DOSES)
    8.9 MMR
           8.9.1 RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA IS SUPPORTING THE GROWTH OF THIS SEGMENT
                    TABLE 89 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES IN THE MARKET
                    TABLE 90 MMR VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 91 NORTH AMERICA: MMR MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.10 VARICELLA
           8.10.1 PROMOTION OF IMMUNIZATION PROGRAMS TO DRIVE THE DEMAND FOR VARICELLA VACCINES
                    TABLE 92 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES IN THE MARKET
                    TABLE 93 VARICELLA VACCINE MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 94 NORTH AMERICA: VARICELLA VACCINES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.11 HEPATITIS
           8.11.1 HIGH PREVALENCE OF HEPATITIS INFECTIONS TO DRIVE THE DEMAND FOR IMMUNIZATION
                    TABLE 95 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES IN THE MARKET
                    TABLE 96 HEPATITIS VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 97 NORTH AMERICA: HEPATITIS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.12 DTP
           8.12.1 INCREASING ACCESSIBILITY OF DTP VACCINES IN DEVELOPING COUNTRIES TO DRIVE MARKET GROWTH
                    TABLE 98 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES IN THE MARKET
                    TABLE 99 DTP VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 100 NORTH AMERICA: DTP MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.13 POLIO
           8.13.1 GOVERNMENT INITIATIVES TO SUPPORT THE GROWTH OF THIS SEGMENT
                    TABLE 101 POLIO VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 102 NORTH AMERICA: POLIO MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.14 COVID-19
           8.14.1 EMERGENCE OF SARS-COV-2 VARIANTS COULD MAKE BOOSTER DOSES NECESSARY
                    TABLE 103 LIST OF WHO PREQUALIFIED COVID-19 VACCINES
                    TABLE 104 COVID-19 VACCINE MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 105 NORTH AMERICA: COVID-19 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 106 COVID-19 VACCINE DELIVERIES, BY COUNTRY (MILLION DOSES)
    8.15 OTHER DISEASE INDICATIONS

TABLE 107 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS
TABLE 108 VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 109 NORTH AMERICA: MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)

9 VACCINES MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 147)
    9.1 INTRODUCTION
           TABLE 110 MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
           TABLE 111 MARKET (INCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
    9.2 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION
           9.2.1 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION ACCOUNTED FOR THE LARGEST MARKET SHARE
                    TABLE 112 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION
                    TABLE 113 VACCINE MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                    TABLE 114 NORTH AMERICA: MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 115 EUROPE: MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 116 ASIA PACIFIC: MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 117 LATIN AMERICA: MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
    9.3 ORAL ADMINISTRATION
           9.3.1 POSSIBILITY OF IRRITATION OF THE GASTRIC MUCOSA IS LIMITING THE GROWTH OF THIS SEGMENT
                    TABLE 118 VACCINE MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                    TABLE 119 NORTH AMERICA: MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 120 EUROPE: MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 121 ASIA PACIFIC: MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 122 LATIN AMERICA: MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
    9.4 OTHER ROUTES OF ADMINISTRATION
           TABLE 123 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
           TABLE 124 NORTH AMERICA: MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 125 EUROPE: MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 126 ASIA PACIFIC: MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 127 LATIN AMERICA: MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)

10 VACCINES MARKET, BY END USER (Page No. - 157)
     10.1 INTRODUCTION
               TABLE 128 MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
     10.2 PEDIATRIC VACCINES
             10.2.1 PEDIATRIC VACCINES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET
                       TABLE 129 PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                       TABLE 130 NORTH AMERICA: PEDIATRIC VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                       TABLE 131 EUROPE: PEDIATRIC MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                       TABLE 132 ASIA PACIFIC: PEDIATRIC MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                       TABLE 133 LATIN AMERICA: PEDIATRIC MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
     10.3 ADULT VACCINES
             10.3.1 ADULT VACCINES SEGMENT TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
                       TABLE 134 ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                       TABLE 135 NORTH AMERICA: ADULT VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                       TABLE 136 EUROPE: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                       TABLE 137 ASIA PACIFIC: ADULT VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                       TABLE 138 LATIN AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)

11 VACCINES MARKET, BY REGION (Page No. - 164)
     11.1 INTRODUCTION
               FIGURE 27 VACCINE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES (EXCLUDING COVID-19 VACCINES)
               TABLE 139 MARKET, BY REGION, 2019–2026 (USD MILLION)
               TABLE 140 MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
     11.2 NORTH AMERICA
               FIGURE 28 NORTH AMERICA: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES)
               TABLE 141 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
               TABLE 142 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2019–2026 (USD MILLION)
               TABLE 143 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
               TABLE 144 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
               TABLE 145 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
               TABLE 146 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.2.1 US
                       11.2.1.1 The US is the largest market for vaccines globally
                                   TABLE 147 US: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2019–2026 (USD MILLION)
                                   TABLE 148 US: MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 149 US: MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 150 US: MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 151 US: MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.2.2 CANADA
                       11.2.2.1 High incidence of infectious diseases is driving the demand for vaccines in the country
                                   TABLE 152 CANADA: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2019–2026 (USD MILLION)
                                   TABLE 153 CANADA: MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 154 CANADA: MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 155 CANADA: MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 156 CANADA: MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
     11.3 EUROPE
               TABLE 157 EUROPE: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
               TABLE 158 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2019–2026 (USD MILLION)
               TABLE 159 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
               TABLE 160 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
               TABLE 161 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
               TABLE 162 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.3.1 GERMANY
                       11.3.1.1 Significant investments in R&D to support market growth
                                   TABLE 163 GERMANY: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 164 GERMANY: MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 165 GERMANY: MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 166 GERMANY: MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.3.2 UK
                       11.3.2.1 Launch of new products and collaborations to support market growth in the UK in the coming years
                                   TABLE 167 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 168 UK: MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 169 UK: MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 170 UK: MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.3.3 FRANCE
                       11.3.3.1 Favorable government initiatives for immunization to support market growth in France
                                   TABLE 171 FRANCE: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 172 FRANCE: MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 173 FRANCE: MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 174 FRANCE: MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.3.4 ITALY
                       11.3.4.1 Italy is the third-largest donor for the International Finance Facility for Immunization
                                   TABLE 175 ITALY: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 176 ITALY: MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 177 ITALY: MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 178 ITALY: MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.3.5 SPAIN
                       11.3.5.1 Increasing investments in vaccine development by private organizations to support market growth in Spain
                                   TABLE 179 SPAIN: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 180 SPAIN: MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 181 SPAIN: MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 182 SPAIN: MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.3.6 REST OF EUROPE
                       TABLE 183 ROE: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                       TABLE 184 ROE: MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                       TABLE 185 ROE: MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                       TABLE 186 ROE: MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
     11.4 ASIA PACIFIC
               TABLE 187 ASIA PACIFIC: HEALTHCARE EXPENDITURE PER CAPITA, BY COUNTRY, 2017 VS. 2018 VS. 2019 (USD)
               FIGURE 29 ASIA PACIFIC: MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES)
               TABLE 188 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
               TABLE 189 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2019–2026 (USD MILLION)
               TABLE 190 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
               TABLE 191 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
               TABLE 192 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
               TABLE 193 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.4.1 CHINA
                       11.4.1.1 Growing investments in the biotechnology sector to drive market growth in China
                                   TABLE 194 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 195 CHINA: MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 196 CHINA: MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 197 CHINA: MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.4.2 JAPAN
                       11.4.2.1 Government initiatives for increasing the accessibility of vaccines to drive market growth in Japan
                                   TABLE 198 JAPAN: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 199 JAPAN: MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 200 JAPAN: MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 201 JAPAN: MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.4.3 INDIA
                       11.4.3.1 Growth of the biotechnology sector and development of new vaccines to support market growth in India
                                   TABLE 202 INDIA: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 203 INDIA: MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 204 INDIA: MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 205 INDIA: MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.4.4 SOUTH KOREA
                       11.4.4.1 Strong government boost to develop vaccine hubs in the country is expected to drive market growth
                                   TABLE 206 SOUTH KOREA: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 207 SOUTH KOREA: MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 208 SOUTH KOREA: MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 209 SOUTH KOREA: MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.4.5 REST OF ASIA PACIFIC
                       TABLE 210 ROAPAC: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                       TABLE 211 ROAPAC: MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                       TABLE 212 ROAPAC: MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                       TABLE 213 ROAPAC: MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
     11.5 LATIN AMERICA
               TABLE 214 LATIN AMERICA: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
               TABLE 215 LATIN AMERICA: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2019–2026 (USD MILLION)
               TABLE 216 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
               TABLE 217 LATIN AMERICA: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
               TABLE 218 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
               TABLE 219 LATIN AMERICA: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.5.1 BRAZIL
                       11.5.1.1 Rising focus on vaccination from governmental and non-governmental organizations to drive market growth
                                   TABLE 220 BRAZIL: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 221 BRAZIL: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 222 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 223 BRAZIL: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.5.2 REST OF LATIN AMERICA
                       TABLE 224 ROLA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                       TABLE 225 ROLA: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                       TABLE 226 ROLA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                       TABLE 227 ROLA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
     11.6 MIDDLE EAST AND AFRICA
             11.6.1 HIGH DEMAND FOR VACCINES DUE TO THE PREVALENCE OF INFECTIOUS DISEASES WILL DRIVE MARKET GROWTH
                       TABLE 228 MIDDLE EAST & AFRICA: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2019–2026 (USD MILLION)
                       TABLE 229 MIDDLE EAST & AFRICA: VACCINE MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                       TABLE 230 MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                       TABLE 231 MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                       TABLE 232 MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 213)
     12.1 OVERVIEW
     12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
               FIGURE 30 KEY PLAYER STRATEGIES IN THE VACCINES MARKET, 2018-2021
     12.3 MARKET SHARE ANALYSIS
               FIGURE 31 VACCINE MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
     12.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
               FIGURE 32 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE VACCINES MARKET, 2016–2020
     12.5 COMPANY EVALUATION QUADRANT
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                       FIGURE 33 VACCINES MARKET: COMPANY EVALUATION QUADRANT, 2020
     12.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 STARTING BLOCKS
             12.6.3 RESPONSIVE COMPANIES
             12.6.4 DYNAMIC COMPANIES
                       FIGURE 34 VACCINES MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
     12.7 DISEASE INDICATION FOOTPRINT OF COMPANIES
               TABLE 233 DISEASE INDICATION PORTFOLIO ANALYSIS: VACCINE MARKET (2020)
     12.8 REGIONAL FOOTPRINT OF COMPANIES
               TABLE 234 REGIONAL FOOTPRINT ANALYSIS: VACCINES MARKET (2020)
     12.9 COMPETITIVE SCENARIO
             12.9.1 PRODUCT LAUNCHERS & APPROVALS
                       TABLE 235 VACCINE MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2018–NOVEMBER 2021
             12.9.2 DEALS
                       TABLE 236 VACCINES MARKET: DEALS, JANUARY 2018–NOVEMBER 2021
             12.9.3 OTHER DEVELOPMENTS
                       TABLE 237 VACCINE MARKET: OTHER DEVELOPMENTS, JANUARY 2018–NOVEMBER 2021

13 COMPANY PROFILES (Page No. - 229)
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
     13.1 KEY COMPANIES
             13.1.1 GLAXOSMITHKLINE PLC
                       TABLE 238 GLAXOSMITHKLINE PLC: BUSINESS OVERVIEW
                       FIGURE 35 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2020)
             13.1.2 MERCK & CO., INC.
                       TABLE 239 MERCK & CO., INC.: BUSINESS OVERVIEW
                       FIGURE 36 MERCK & CO., INC.: COMPANY SNAPSHOT (2020)
             13.1.3 PFIZER, INC.
                       TABLE 240 PFIZER, INC.: BUSINESS OVERVIEW
                       FIGURE 37 PFIZER, INC.: COMPANY SNAPSHOT (2020)
             13.1.4 SANOFI SA
                       TABLE 241 SANOFI SA: BUSINESS OVERVIEW
                       FIGURE 38 SANOFI SA: COMPANY SNAPSHOT (2020)
             13.1.5 CSL LIMITED
                       TABLE 242 CSL LIMITED: BUSINESS OVERVIEW
                       FIGURE 39 CSL LIMITED: COMPANY SNAPSHOT (2020)
             13.1.6 EMERGENT BIOSOLUTIONS, INC.
                       TABLE 243 EMERGENT BIOSOLUTIONS, INC.: BUSINESS OVERVIEW
                       FIGURE 40 MERGENT BIOSOLUTIONS, INC.: COMPANY SNAPSHOT (2020)
             13.1.7 JOHNSON & JOHNSON
                       TABLE 244 JOHNSON & JOHNSON: BUSINESS OVERVIEW
                       FIGURE 41 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2020)
             13.1.8 ASTRAZENECA PLC
                       TABLE 245 ASTRAZENECA PLC: BUSINESS OVERVIEW
                       FIGURE 42 ASTRAZENECA PLC: COMPANY SNAPSHOT (2020)
             13.1.9 SERUM INSTITUTE OF INDIA PVT., LTD.
                       TABLE 246 SERUM INSTITUTE OF INDIA PVT. LTD.: BUSINESS OVERVIEW
             13.1.10 BAVARIAN NORDIC A/S
                       TABLE 247 BAVARIAN NORDIC A/S: BUSINESS OVERVIEW
                       FIGURE 43 BAVARIAN NORDIC A/S: COMPANY SNAPSHOT (2020)
             13.1.11 MITSUBISHI TANABE PHARMA CORPORATION
                       TABLE 248 MITSUBISHI TANABE PHARMA CORPORATION: BUSINESS OVERVIEW
             13.1.12 DAIICHI SANKYO COMPANY, LIMITED
                       TABLE 249 DAIICHI SANKYO COMPANY, LIMITED: BUSINESS OVERVIEW
                       FIGURE 44 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2020)
             13.1.13 PANACEA BIOTEC
                       TABLE 250 PANACEA BIOTEC: BUSINESS OVERVIEW
                       FIGURE 45 PANACEA BIOTEC: COMPANY SNAPSHOT (2020)
             13.1.14 BIOLOGICAL E LIMITED
                       TABLE 251 BIOLOGICAL E LIMITED: BUSINESS OVERVIEW
             13.1.15 BHARAT BIOTECH
                       TABLE 252 BHARAT BIOTECH: BUSINESS OVERVIEW
             13.1.16 NOVAVAX, INC.
                       TABLE 253 NOVAVAX, INC.: BUSINESS OVERVIEW
                       FIGURE 46 NOVAVAX, INC.: COMPANY SNAPSHOT (2020)
             13.1.17 FSUE NPO MICROGEN
                       TABLE 254 FSUE NPO MICROGEN: BUSINESS OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
     13.2 OTHER COMPANIES
             13.2.1 SINOVAC BIOTECH LTD.
             13.2.2 INCEPTA VACCINE LTD.
             13.2.3 VALNEVA SE
             13.2.4 VBI VACCINES INC.
             13.2.5 PT BIO FARMA (PERSERO)
             13.2.6 INOVIO PHARMACEUTICALS, INC.
             13.2.7 CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
             13.2.8 INDIAN IMMUNOLOGICALS LIMITED

14 APPENDIX (Page No. - 294)
     14.1 DISCUSSION GUIDE
     14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     14.3 AVAILABLE CUSTOMIZATIONS
     14.4 RELATED REPORTS
     14.5 AUTHOR DETAILS

This market research study involves the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global vaccines market. Interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market prospects. The vaccine market size was estimated through various secondary research approaches and triangulated with inputs from primary research.

Secondary Research

The secondary sources referred to for this research study include publications from government sources, such as the World Health Organization, Organisation for Economic Co-operation and Development, World Bank, Centers for Disease Control and Prevention, American Cancer Society, US Food and Drug Administration, European Commission, European Centre for Disease Prevention and Control, National Institutes of Health, National Institute of Allergy and Infectious Diseases, United Nations’ Children Fund, Gavi - The Vaccine Alliance, Pan American Health Organization, Biomedical Advanced Research & Development Authority, Program for Appropriate Technology in Health (PATH), Coalition for Epidemic Preparedness Innovations (CEPI), and International AIDS Vaccine Initiative (IAVI). Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations, among others. Secondary data was collected and analyzed to arrive at the overall size of the global vaccines market, which was validated through primary research.

Primary Research

After acquiring basic knowledge about the global vaccines market scenario through secondary research, extensive primary research was conducted after acquiring basic knowledge about the global vaccines market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (such as personnel from the purchase & sales department, research organizations, and doctors) and supply side (such as C-level and D-level executives, product managers, manufacturing managers, marketing & sales managers of key manufacturers, distributors, and channel partners, among others) across four major regions—North America, Europe, the Asia Pacific, and the Rest of the World. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

Vaccines Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the vaccines market was estimated through different approaches. A detailed market estimation approach was followed to estimate and validate the global market value and other dependent submarkets, as mentioned below. Both top-down and bottom-up approaches were used to estimate and validate the total size of the vaccines market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

The key players in the industry and market have been identified through extensive secondary research
The revenues generated from the vaccines business of leading players have been determined through primary and secondary research
All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

To define, describe, and forecast the global vaccines market on the basis of technology, type, disease indication, route of administration, end user, and region
To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall vaccines market
To analyze the market opportunities for stakeholders and provide details of the competitive landscape for key players
To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific (APAC), Latin America, and the Middle East and Africa (MEA)
To profile the key players and comprehensively analyze their product portfolios, market shares and rankings, and core competencies
To track and analyze competitive developments, such as acquisitions, product launches, expansions, regulatory approvals, agreements, partnerships, and collaborations in the global vaccines market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographic Analysis

Further breakdown of the European vaccines market into countries from the Rest of Europe.
Further breakdown of the Asia Pacific vaccines market into countries from the Rest of the APAC.
Further breakdown of the Latin America vaccines market into Brazil, Mexico, and the Rest of Latin America.